BIEGi-1 is a potent and selective binary inhibitor of EGFR that effectively blocks EGFR-catalyzed nucleotide exchange and disrupts the EGFR–Rheb interaction. It robustly inhibits both EGFR kinase activity and mTORC1 signaling in EGFR-mutant cancer cells. BIEGi-1 exhibits significant anti-proliferative effects with an IC50 of 17 nM for PC9 and 20 nM for HCC827.

CT1113 is a potent dual inhibitor of USP25 and USP28 that effectively reduces c-MYC levels and exhibits strong anti-tumor activity. It can be used in research on colon and pancreatic cancers.

CT1113 is a potent dual inhibitor of USP25 and USP28 that effectively reduces c-MYC levels and exhibits strong anti-tumor activity. It can be used in research on colon and pancreatic cancers.

CT1113 is a potent dual inhibitor of USP25 and USP28 that effectively reduces c-MYC levels and exhibits strong anti-tumor activity. It can be used in research on colon and pancreatic cancers.

Col003 is a potent inhibitor of Hsp47 that competitively binds to the collagen-binding site on Hsp47 and inhibited the interaction between Hsp47 and collagen with an IC50 of 1.8 μM. It can be used in research as a potential lead compound for the treatment of fibrosis.

Col003 is a potent inhibitor of Hsp47 that competitively binds to the collagen-binding site on Hsp47 and inhibited the interaction between Hsp47 and collagen with an IC50 of 1.8 μM. It can be used in research as a potential lead compound for the treatment of fibrosis.

CT1113 is a potent dual inhibitor of USP25 and USP28 that effectively reduces c-MYC levels and exhibits strong anti-tumor activity. It can be used in research on colon and pancreatic cancers.

Biotin-HPDP is a thiol-specific biotinylating reagent that forms a reversible disulfide bond with free cysteine residues on proteins or peptides. It is widely used to selectively tag and detect sulfhydryl groups, especially in biochemical assays. In the Biotin Switch assay, Biotin-HPDP labels newly exposed cysteine thiols after reduction of S-nitrosylated or S-sulfhydrated proteins, enabling detection […]

Col003 is a potent inhibitor of Hsp47 that competitively binds to the collagen-binding site on Hsp47 and inhibited the interaction between Hsp47 and collagen with an IC50 of 1.8 μM. It can be used in research as a potential lead compound for the treatment of fibrosis.

Col003 is a potent inhibitor of Hsp47 that competitively binds to the collagen-binding site on Hsp47 and inhibited the interaction between Hsp47 and collagen with an IC50 of 1.8 μM. It can be used in research as a potential lead compound for the treatment of fibrosis.